A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Status:
Completed
Trial end date:
2018-12-27
Target enrollment:
Participant gender:
Summary
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in
combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a
direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib
combined with dabrafenib alone.